MKMuhammad Haris Khan

Muhammad Haris Khan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muhammad Haris Khan has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical outcomes of impella compared with intra-aortic balloon pump support in cardiogenic shock: a systematic review and meta-analysis

    by Anfal Khan, Sadia Mubarak, Aleena Amir Malik, Waqas Kareem, Zain Shahzad, Muhammad Haris Khan, Hafsa Rehman, Abdur Rehman, Jamshid Arify, Shakir Ullah, et al.

  • Open Access

    Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials

    by Muhammad Fahad Iqbal Khan, Zain Afridi, Muhammad Haris Khan, Muhammad Zahid Anwar, Ali Nawaz, Umama Malik, Muhammad Usama Nawaz, Malik Sheheryar, Muhammad Hamad Ali, Huda Habib, et al.

    The clinical benefit of simvastatin as an adjunctive treatment in liver cirrhosis remains inconclusive, with prior syntheses becoming outdated after the publication of the largest trial on the topic. This updated meta-analysis aimed to evaluate the therapeutic impact of simvastatin in cirrhotic patients. A systematic search was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov using MeSH terms related to “Simvastatin” and “Liver Cirrhosis.” Randomized controlled trials (RCTs) comparing simvastatin to placebo or any other drugs were included. Nine RCTs, including 966 patients, were analyzed. Simvastatin showed no statistically significant effect on all-cause mortality, although a borderline trend toward a 37% relative risk reduction was observed [risk ratio (RR): 0.63; 95% confidence interval (CI): 0.38–1.04; P = 0.07], suggesting a potentially clinically meaningful effect. No significant differences were found in bleeding (RR: 0.70; 95% CI: 0.45–1.08), development of ascites (RR: 0.91; 95% CI: 0.69–1.21), hepatorenal syndrome (RR: 0.85; 95% CI: 0.64–1.87), hepatic venous pressure gradient (standardized mean difference [SMD]: −0.19; 95% CI: −0.49 to 0.11), wedged hepatic venous pressure (SMD: −0.11; 95% CI: −0.44 to 0.23), free hepatic venous pressure (SMD: 0.04; 95% CI: −0.21 to 0.29), and adverse events (RR: 1.04; 95% CI: 0.95–1.15), serious adverse events (RR: 0.93; 95% CI: 0.75–1.15), and musculoskeletal adverse events (RR: 1.27; 95% CI: 0.87–1.85). Overall, simvastatin did not demonstrate statistically significant reductions in cirrhosis-related complications. Nevertheless, the observed trend toward lower mortality suggests a possible protective effect that existing trials may be underpowered to confirm. Larger, well-designed RCTs are warranted to clarify its impact on survival outcomes.

  • Open Access

    Hemodynamic Patterns in Septic Cardiomyopathy: Insights From Echocardiographic Parameters and Biomarker Analysis

    by Rabia Jaffar, Ahmed Jamal Chaudhary, Marium Nadeem Khan, Hamza Wakil, Muhammad Waseem Hussain, Mohammad Ibrahim Rasool, Taha Nasim, Muhammad Haris Khan, Ali Raza

    Introduction Septic cardiomyopathy (SCM) refers to an acute, reversible impairment of cardiac performance. This study aimed to evaluate hemodynamic patterns in SCM using echocardiographic parameters and cardiac biomarkers in critically ill patients. Materials and methods A 12-month prospective observational study was conducted at a single tertiary care center in Peshawar, Pakistan. Adult ICU patients with sepsis or septic shock underwent transthoracic echocardiography (TTE) within 48 hours of admission, with a repeat study on day 5 or earlier if clinically indicated. Left ventricular (LV) and right ventricular (RV) systolic and diastolic functions were assessed, including global longitudinal strain (GLS) and RV free-wall strain. High-sensitivity troponin I (hs-TnI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were measured on days 1 and 3. Associations between cardiac dysfunction and in-hospital mortality were analyzed using multivariable logistic regression after adjusting for age, sex, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, and vasopressor use. Results Among 122 patients, the prevalence of SCM, defined by LV GLS > −17%, was high, with concurrent RV dysfunction observed in a significant proportion. Elevated hs-TnI and NT-proBNP levels correlated with impaired GLS and adverse outcomes. After multivariable adjustment, GLS impairment and elevated NT-proBNP remained independently associated with in-hospital mortality. Conclusions In this South Asian cohort with sepsis or septic shock, combined strain-based echocardiography and biomarker profiling revealed distinct patterns of myocardial dysfunction associated with early mortality. While these findings highlight the prognostic utility of GLS and NT-proBNP, they should be interpreted as associations rather than causal effects. Larger multicenter studies with extended follow-up and incorporation of additional biomarkers and advanced imaging are needed to validate these observations and clarify underlying pathophysiological mechanisms.